Recent Quotes (30 days)

You have no recent quotes
chg | %


(Public, NASDAQ:CRME)   Watch this stock  
Find more results for CRME
+0.01 (0.32%)
Real-time:   9:30AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.15 - 3.15
52 week 2.35 - 6.36
Open 3.15
Vol / Avg. 0.00/82,948.00
Mkt cap 101.33M
P/E     -
Div/yield     -
EPS -0.79
Shares 31.90M
Beta 1.42
Inst. own 147%
May 11, 2017
Q1 2017 Cardiome Pharma Corp Earnings Release (Estimated) Add to calendar
May 1, 2017
Cardiome Pharma Corp at Bloom Burton & Co. Healthcare Investor Conference - 3:30PM EDT - Add to calendar
Mar 7, 2017
Q4 2016 Cardiome Pharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -79.61% -77.68%
Operating margin -68.27% -63.17%
EBITD margin - -45.80%
Return on average assets -32.10% -34.04%
Return on average equity -60.51% -72.72%
Employees 85 -
CDP Score - -


1441 Creekside Dr 6th Floor
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Officers and directors

W. James O'Shea Independent Chairman of the Board
Bio & Compensation  - Reuters
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jennifer Archibald CPA Chief Financial Officer
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
Hugues Sachot Senior Vice President - Sales
Bio & Compensation  - Reuters
David C. Dean Vice President - Investor Relations and Business Development
Bio & Compensation  - Reuters
David D. McMasters J.D. Corporate General Counsel
Bio & Compensation  - Reuters
Richard M. Glickman LL.D. Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark H.N. Corrigan M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Robert James Meyer M.D. Independent Director
Bio & Compensation  - Reuters